© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 18, 1530-1532,
September 15, 1999
© 1999 Oxford University Press
NEWS |
Stem Cell Maneuvers Target Bone Marrow Toxicity
Prospects for high-dose chemotherapy seemed to dim last spring with the news that in only one of five breast cancer studies had patients with advanced disease or at high risk of recurrence fared significantly better on it than on standard lower-dose regimens. Despite that, the cancer research community is far from ready to give up on HDC striving instead to improve the treatment.
HDC would be highly lethal were it not for autologous bone marrow transplants which, because they contain blood-forming stem cells, can repair the damage the drugs do to the body's immune system. However, the transplants actually portions of the patient's own marrow which are removed before HDC and then returned are themselves vulnerable to injury from these drugs. HDC is, therefore, a once-only option for cancer patients and it is that limitation that some researchers are trying to address.
"Bone marrow toxicity is the
Vexing Hurdle
Testicular Cancer
Defanging BCNU
Clinical Proof